Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 356

1.

The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.

Jeselsohn R, De Angelis C, Brown M, Schiff R.

Curr Oncol Rep. 2017 May;19(5):35. doi: 10.1007/s11912-017-0591-8. Review.

PMID:
28374222
2.

CDK4/6 inhibitors in HER2-positive breast cancer.

Corona SP, Ravelli A, Cretella D, Cappelletti MR, Zanotti L, Dester M, Gobbi A, Petronini PG, Generali D.

Crit Rev Oncol Hematol. 2017 Apr;112:208-214. doi: 10.1016/j.critrevonc.2017.02.022. Epub 2017 Feb 24. Review.

PMID:
28325261
3.

Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.

Xiong R, Zhao J, Gutgesell LM, Wang Y, Lee S, Karumudi B, Zhao H, Lu Y, Tonetti DA, Thatcher GR.

J Med Chem. 2017 Feb 23;60(4):1325-1342. doi: 10.1021/acs.jmedchem.6b01355. Epub 2017 Feb 10.

PMID:
28117994
4.

Fulvestrant for hormone-sensitive metastatic breast cancer.

Lee CI, Goodwin A, Wilcken N.

Cochrane Database Syst Rev. 2017 Jan 3;1:CD011093. doi: 10.1002/14651858.CD011093.pub2. Review.

PMID:
28043088
5.

Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.

Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS.

JAMA Oncol. 2017 Mar 1;3(3):313-319. doi: 10.1001/jamaoncol.2016.3904.

PMID:
27832260
6.

Aromatase inhibitors with or without luteinizing hormone-releasing hormone agonist for metastatic male breast cancer: report of four cases and review of the literature.

Kuba S, Ishida M, Oikawa M, Nakamura Y, Yamanouchi K, Tokunaga E, Taguchi K, Esaki T, Eguchi S, Ohno S.

Breast Cancer. 2016 Nov;23(6):945-949. Epub 2016 Feb 15. Review.

PMID:
26879549
7.

Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.

Niraula S, Ocana A.

Cancer Treat Rev. 2016 Nov;50:168-174. doi: 10.1016/j.ctrv.2016.09.011. Epub 2016 Sep 20. Review.

PMID:
27693931
8.

Endocrine treatment in breast cancer: Cure, resistance and beyond.

Tryfonidis K, Zardavas D, Katzenellenbogen BS, Piccart M.

Cancer Treat Rev. 2016 Nov;50:68-81. doi: 10.1016/j.ctrv.2016.08.008. Epub 2016 Sep 7. Review.

PMID:
27643748
9.

Endocrine therapy for hormone treatment-naïve advanced breast cancer.

Martin M, Lopez-Tarruella S, Gilarranz YJ.

Breast. 2016 Aug;28:161-6. doi: 10.1016/j.breast.2016.05.015. Epub 2016 Jun 18. Review.

10.

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).

Lerebours F, Rivera S, Mouret-Reynier MA, Alran S, Venat-Bouvet L, Kerbrat P, Salmon R, Becette V, Bourgier C, Cherel P, Boussion V, Balleyguier C, Thibault F, Lavau-Denes S, Nabholz JM, Sigal B, Trassard M, Mathieu MC, Martin AL, Lemonnier J, Mouret-Fourme E.

Cancer. 2016 Oct;122(19):3032-40. doi: 10.1002/cncr.30143. Epub 2016 Jun 17.

PMID:
27315583
11.

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.

Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B, Forero-Torres A, Lee SC, de Boer R, Petrakova K, Vallentin S, Perez EA, Piccart M, Ellis M, Winer E, Gendreau S, Derynck M, Lackner M, Levy G, Qiu J, He J, Schmid P.

Lancet Oncol. 2016 Jun;17(6):811-21. doi: 10.1016/S1470-2045(16)00106-6. Epub 2016 May 4.

PMID:
27155741
12.

Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion.

JavanMoghadam S, Weihua Z, Hunt KK, Keyomarsi K.

Cell Cycle. 2016 Jun 17;15(12):1579-90. doi: 10.1080/15384101.2016.1166327. Epub 2016 Apr 6.

13.
14.

Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials.

Graham J, Pitz M, Gordon V, Grenier D, Amir E, Niraula S.

Cancer Treat Rev. 2016 Apr;45:1-6. doi: 10.1016/j.ctrv.2016.02.004. Epub 2016 Feb 22. Review.

PMID:
26922660
15.

Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.

Sansone P, Ceccarelli C, Berishaj M, Chang Q, Rajasekhar VK, Perna F, Bowman RL, Vidone M, Daly L, Nnoli J, Santini D, Taffurelli M, Shih NN, Feldman M, Mao JJ, Colameco C, Chen J, DeMichele A, Fabbri N, Healey JH, Cricca M, Gasparre G, Lyden D, Bonafé M, Bromberg J.

Nat Commun. 2016 Feb 9;7:10442. doi: 10.1038/ncomms10442.

16.

A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition.

Zucchini G, Armstrong AC, Wardley AM, Wilson G, Misra V, Seif M, Ryder WD, Cope J, Blowers E, Howell A, Palmieri C, Howell SJ.

Eur J Cancer. 2015 Dec;51(18):2725-31. doi: 10.1016/j.ejca.2015.08.028. Epub 2015 Nov 18.

PMID:
26597446
17.

Development of cell-cycle checkpoint therapy for solid tumors.

Tamura K.

Jpn J Clin Oncol. 2015 Dec;45(12):1097-102. doi: 10.1093/jjco/hyv131. Epub 2015 Oct 20. Review.

PMID:
26486823
18.

Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.

Pouget M, Abrial C, Planchat E, Van Praagh I, Arbre M, Kwiatkowski F, Dubray-Longeras P, Devaud H, Dohou J, Herviou P, Mahammedi H, Durando X, Chollet P, Mouret-Reynier MA.

Oncology. 2015;89(6):319-31. doi: 10.1159/000437230. Epub 2015 Oct 13.

PMID:
26457979
19.

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.

Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasiówka M, Hewson N, Rukazenkov Y, Robertson JF.

J Clin Oncol. 2015 Nov 10;33(32):3781-7. doi: 10.1200/JCO.2015.61.5831. Epub 2015 Sep 14.

20.

Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study.

Balduzzi A, Bagnardi V, Sandri MT, Dellapasqua S, Cardillo A, Montagna E, Cancello G, Iorfida M, Ghisini R, Viale G, Intra M, Luini A, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2015 Oct;15(5):e257-62. doi: 10.1016/j.clbc.2015.03.007. Epub 2015 Apr 30.

PMID:
26362840

Supplemental Content

Loading ...
Support Center